Search results
How Neuroscience Is Leading the Next Wave of Skin-Care Innovation
PopSugar· 1 day agoNot to mention, aromatherapy uses scent to affect mood and CBD products bind to cannabinoid...
Canandaigua National Bank & Trust Co. Has $15.92 Million Stake in Johnson & Johnson (NYSE:JNJ)
ETF DAILY NEWS· 3 days agoCanandaigua National Bank & Trust Co. cut its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.9% in the 1st quarter, according to its most recent Form 13F filing with the ...
How AI Is Revolutionizing Drug Development
New York Times· 5 days agoIn high-tech labs, workers are generating data to train A.I. algorithms to design better medicine, faster. Steve Lohr reported from the Terray...
Jude Bellingham fans discuss hyperpigmentation over footballer's appearance
Yahoo Life UK· 3 days agoRead more about skin conditions: How a healthy gut microbiome can give you better winter skin (Yahoo...
Johnson & Johnson (NYSE:JNJ) Shares Sold by Smith Shellnut Wilson LLC ADV
ETF DAILY NEWS· 6 days agoSmith Shellnut Wilson LLC ADV decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 5.6% in the fourth quarter, according to its most recent Form 13F filing with ...
Here Comes the Sun: We Are Your Summer Skincare Experts
Lancaster Online· 2 days agoSummer is finally here and, for most of us, that means more time in the sun - whether it’s relaxing...
AbbVie (NYSE:ABBV) Shares Up 0%
ETF DAILY NEWS· 7 days agoShares of AbbVie Inc. (NYSE:ABBV – Get Free Report) shot up 0% during mid-day trading on Thursday . The company traded as high as $166.45 and last traded at $166.15. ABBV has been the topic ...
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs
Zacks· 1 day agoFDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Imfinzi.
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 2 days agoWith the arrival of biosimilar competition for its blockbuster drug Humira, AbbVie has said much of its sales growth potential lies with these two anti-inflammatories. In April, the North Chicago ...
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio...
Morningstar· 3 days agoApproval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 and a 52-week maintenance study, COMMAND2Data showed that clinical remission,
